The Role of the Upper Colliculus in the Idiopathic Blepharospasm

Blepharospasm, Benign Essential Clinical Trial

— COLL-BSP  

Official title:

The Role of the Upper Colliculus in the Idiopathic Blepharospasm : a Pilot Study in Functional MRI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03903341
• Other study ID #: 38RC17.399
• Status: Completed
• Phase: N/A
• Start date: November 20, 2019
• Est. completion date: November 19, 2021

Study information

• Verified date: September 2022
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study aims at investigating the role of superior colliculus in patients with idiopathic blepharospasm (BSP) de novo, compared to healthy subjects.

Description:

The objective of the study is to investigate the function of the superior colliculus (SC) related to visual stimulation by means of fMRI (functional magnetic resonance imaging) in patients with idiopathic BSP compared to healthy subjects. The hypothesis is that SC function is impaired in BSP (role of biomarker of SC).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: November 19, 2021
• Est. primary completion date: November 19, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Non treated idiopathic blepharospasm

• Age: 30- 70 years

Exclusion Criteria:

• Under the following treatments: Botulin toxin, anticholinergic, benzodiazepines, baclofen, beta- and alpha-blockers collyrium

• No MRI Contraindication

Related Conditions & MeSH terms

• Blepharospasm
• Blepharospasm, Benign Essential

Intervention

Other:
• fMRI
bold signal in visual pathway

Locations

Country	Name	City	State
France	CHU Grenoble Alpes	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual pathways fMRI	To measure the bold signal in superior colliculus and lateral geniculate corpus	In a five months period after inclusion